IceCure Medical, a Caesarea developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced that data from its ICE3 trial of ProSense treatment in early-stage breast cancer were presented at the Radiological Society of North America’s 2024 Annual Meeting on 5th December in Chicago.
Dr. Kenneth Tomkovich, Co-Principal Investigator of the ICE3 trial, said: “The significance of the ICE3 results in the field of radiology, especially among breast radiologists, cannot be overstated. As the largest study of its kind, ICE3 provides crucial data that can support the shift towards the de- escalation of breast cancer care with cryoablation as a less invasive procedure, enabling the cohort of patients included in ICE3 to have a safe and effective option to surgical lumpectomy.”
The findings presented included:
- The overall five-year recurrence rate of 3.7% in combination with adjuvant endocrine therapy and 4.3% in the eligible ICE3 trial population is similar to reported recurrence rates for the current standard of care, surgical lumpectomy.
- Substantial benefits, as compared to surgery, include performance in an outpatient setting using local anaesthesia, the only reported adverse events being minor in severity, and 100% patient satisfaction with cosmetic outcomes.
- Results of the ICE3 trial suggest that cryoablation for small low-risk breast cancers is a safe and effective primary treatment option alternative to surgical lumpectomy.
- Sentinel lymph node biopsy is likely not required in this cohort of patients.